Intervention: Nirmatrelvir/Ritonavir

Rotundo

Italy
|
2022-2023
  • Adults (18-64 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Drysdale 3

United Kingdom
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Primary care
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir

Gentile

Italy
|
2023-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab

Rinaldi

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Molnupiravir

Basoulis

Greece
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir

Patel

United Kingdom
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Community
  • Primary care
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir

PanoramicNOR

Norway
|
2023-2026
  • Adults (18-64 years)
  • General population
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir

Mazzitelli

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

ESOA-19

Portugal
|
2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Evans

United Kingdom
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Outpatient clinic
  • Community
  • Non-hospital health centre
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir